English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 936102 Online Users : 607
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
Institute of Molecular and Genomic Medicine
Institute of Biotechnology and Pharmaceutical Research
Institute of Biomedical Engineering and Nanomedicine
Immunology Research Center
Center for Neuropsychiatric Research
Institute of Cellular and Systems Medicine
National Institute of Infectious Diseases and Vaccinology
Institute of Population Health Sciences
National Institute of Cancer Research
National Institute of Environmental Health Sciences
National Mosquito-Borne Diseases Control Research Center
National Center for Geriatrics and Welfare Research
Forum
Center of Biomedical Resource
NHRI Graduate Student Program
Core Instrument Center
Pathology Core Laboratory
Laboratory Animal Center
Administrative Units
圖書館
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
NHRI
>
Items for Author
Loading...
Category
Loading community tree, please wait....
Year
Loading year class tree, please wait....
Items for Author "Boku, N"
Return to Browse by Author
Showing 21 items.
Collection
Date
Title
Relation
Bitstream
[陳立宗] 會議論文/會議摘要
2020-02
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
-
[陳立宗] 會議論文/會議摘要
2019-02
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
-
[陳立宗] 會議論文/會議摘要
2018-05
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
-
[陳立宗] 會議論文/會議摘要
2018-02
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
-
[陳立宗] 會議論文/會議摘要
2017-02
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
-
[陳立宗] 會議論文/會議摘要
2017-09
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
-
[陳立宗] 會議論文/會議摘要
2017-09
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
-
[陳立宗] 會議論文/會議摘要
2017-09
ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer
-
[陳立宗] 會議論文/會議摘要
2017-09
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer
-
[陳立宗] 會議論文/會議摘要
2018-09
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
-
[陳立宗] 會議論文/會議摘要
2020-09
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
-
[陳立宗] 期刊論文
2022-04
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
-
[陳立宗] 期刊論文
2024-08-20
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
-
[陳立宗] 期刊論文
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
-
[陳立宗] 期刊論文
2019-02
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4)
-
[陳立宗] 期刊論文
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
-
[陳立宗] 期刊論文
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
-
[陳立宗] 期刊論文
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
-
[陳立宗] 期刊論文
2019-03
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
-
[陳立宗] 期刊論文
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
-
[陳立宗] 期刊論文
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback